Theoretical Investigation by DFT and Molecular Docking of Synthesized Oxidovanadium(IV)-Based Imidazole Drug Complexes as Promising Anticancer Agents

Vanadium compounds have been set in various fields as anticancer, anti-diabetic, anti-parasitic, anti-viral, and anti-bacterial agents. This study reports the synthesis and structural characterization of oxidovanadium(IV)-based imidazole drug complexes by the elemental analyzer, molar conductance, magnetic moment, spectroscopic techniques, as well as thermal analysis. The obtained geometries were studied theoretically using density functional theory (DFT) under the B3LYP level. The DNA-binding nature of the ligands and their synthesized complexes has been studied by the electronic absorption titrations method. The biological studies were carried with in-vivo assays and the molecular docking method. The EPR spectra asserted the geometry around the vanadium center to be a square pyramid for metal complexes. The geometries have been confirmed using DFT under the B3LYP level. Moreover, the quantum parameters proposed promising bioactivity of the oxidovanadium(IV) complexes. The results of the DNA-binding revealed that the investigated complexes bind to DNA via non-covalent mode, and the intrinsic binding constant (K_b) value for the [VO(SO₄)(MNZ)₂] H₂O complex was promising, which was 2.0 × 10⁶ M⁻¹. Additionally, the cytotoxic activity of the synthesized complexes exhibited good inhibition toward both hepatocellular carcinoma (HepG-2) and human breast cancer (HCF-7) cell lines. The results of molecular docking displayed good correlations with experimental cytotoxicity findings. Therefore, these findings suggest that our synthesized complexes can be introduced as effective anticancer agents.

Vanadium-Flavonoid Complexes: A Promising Class of Molecules for Therapeutic Applications

Several reports have revealed the superior biological activity of metal ion-flavonoid complexes when compared with the parent flavonoid. Among the different metal ions explored, vanadium and its compounds are in the forefront because of their anticancer and antidiabetic properties. However, the toxicity of vanadium-based ions and their inorganic derivatives limits their therapeutic applications. Complexation of vanadium with flavonoids not only reduces its adverse effects but also augments its biological activity. This Review discusses the nature of coordination in vanadium-flavonoid complexes, their structure-activity correlations, with special emphasis on their therapeutic activities. Several investigations suggest that the superior biological activity of vanadium complexes arise because of their ability to regulate metabolic pathways distinct from those acted upon by vanadium alone. These studies serve to decipher the underlying molecular mechanism of vanadium-flavonoid complexes that can be explored further for generating a series of novel compounds with improved pharmacological and therapeutic performance.

Crystal structures of a series of bis-(acetyl-aceto-nato)oxovanadium(IV) complexes containing N-donor pyridyl ligands

Crystal structures for a series of bis-(acetyl-acetonato)oxovanadium(IV) complexes containing N-donor pyridyl ligands are reported, namely, bis-(acetyl-acetonato-κ² O,O')oxido(pyridine-κN)vanadium(IV), [V(C₅H₇O₂)₂O(C₅H₅N)], 1, bis-(acetyl-acetonato-κ² O,O')oxido(pyridine-4-carbo-nitrile-κN)vanadium(IV), [V(C₅H₇O₂)₂O(C₆H₄N₂)], 2, and bis-(acetyl-acetonato-κ² O,O')(4-meth-oxy-pyridine-κN)oxidovanadium(IV), [V(C₅H₇O₂)₂O(C₆H₇NO)], 3, Compounds 1-3 have the formulae VO(C₅H₇O₂)₂ L, where L = pyridine (1), 4-cyano-pyridine (2), and 4-meth-oxy-pyridine (3). Compound 1 was previously reported [Meicheng et al. (1984 ▸). Kexue Tongbao, 29, 759-764 and DaSilva, Spiazzi, Bortolotto & Burrow (2007). Acta Crystallogr., E63, m2422] and redetermined here at cryogenic temperatures. Compounds 1 and 2 as pyridine and 4-cyano-pyridine adducts, respectively, crystallize as distorted octa-hedral structures with the oxo and pyridyl ligands trans to one another. A crystallographic twofold axis runs through the O-V-N bonds. Compound 3 containing a 4-meth-oxy-pyridine ligand crystallizes as a distorted octa-hedral structure with the oxo and pyridyl ligands cis to one other, removing the twofold symmetry seen in the other complexes.

In vitro apoptosis-induction, antiproliferative and BSA binding studies of a oxidovanadium(V) complex

In our ongoing efforts to develop novel trace metal complexes with therapeutically interesting properties, a neutral mono nuclear oxidomethoxidovanadium(V) complex, [V^VO(OCH₃)(hpdbal-sbdt)] (1) and a μ-O bridged dinuclear oxidovanadium(V) complex, [{V^VO(hpdbal-sbdt)}₂μ-O] (2) [H₂hpdbal-sbdt (I) is a tridentate and dibasic ONS^2- donor ligand obtained through the Schiff base reaction of 2-hydroxy-5-(phenyldiazenyl)benzaldehyde (Hhpdbal) and S-benzyldithiocarbazate (Hsbdt)] have been synthesized and characterized by various analytical techniques such as TGA, EDS, ATR-IR, UV-Vis, CV, ¹H NMR, ¹³C NMR and ⁵¹V NMR. Single-crystal X-ray diffraction analysis of 1 confirms the coordination of phenolate oxygen, imine nitrogen and thioenolate sulfur of the ligand to the vanadium center with a distorted tetragonal-pyramidal geometry. The compound 2 triggered apoptotic and reproductive death of the cancer cells in vitro with 76% and 62% growth inhibition of human breast adenocarcinoma (MCF-7) and human lung carcinoma cells (A549) respectively. The compound 2 was found to be sufficiently stable over a wide window of physiological pH. The complex 2 was studied further for its interaction with a drug carrier protein BSA with the aid of spectroscopic techniques viz. fluorescence, temperature controlled UV-vis and deconvoluted IR techniques.